Genomics and proteomics in renal cell carcinoma: Diagnosis, prognosis, and treatment selection

被引:4
|
作者
Jones J. [1 ]
Pantuck A.J. [1 ]
机构
[1] Department of Urology, David Geffen School of Medicine at UCLA, 66-118 Center for Health Sciences, Los Angeles
关键词
Renal Cell Carcinoma; Sorafenib; Sunitinib; Temsirolimus; Clear Cell Renal Cell Carcinoma;
D O I
10.1007/s11934-008-0004-5
中图分类号
学科分类号
摘要
The term renal cell carcinoma (RCC) once referred to a single entity but now encompasses a spectrum of diverse epithelial tumors with a common derivation from the renal tubular epithelium. The variable course of RCC remains problematic for patient management, despite advances in diagnosis and improved understanding of prognostic factors. However, powerful, high-throughput technologies that now analyze the entire genome and proteome promise to elucidate the heterogeneity of this disease and eventually enable a patient-tailored, individualized medicine. This review considers the clinical relevance and general significance of gene expression and protein-profiling studies. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码:9 / 14
页数:5
相关论文
共 50 条
  • [1] Treatment Selection for Patients With Metastatic Renal Cell Carcinoma
    Atkins, Michael B.
    Choueiri, Toni K.
    Cho, Daniel
    Regan, Meredith
    Signoretti, Sabina
    CANCER, 2009, 115 (10) : 2327 - 2333
  • [2] VHL inactivation in renal cell carcinoma:: implications for diagnosis, prognosis and treatment
    Rathmell, W. Kimryn
    Chen, Shufen
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (01) : 63 - 73
  • [3] Treatment of metastatic renal cell carcinoma
    David J. Reeves
    Chin Y. Liu
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 11 - 25
  • [4] Treatment of metastatic renal cell carcinoma
    Reeves, David J.
    Liu, Chin Y.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 11 - 25
  • [5] Tivozanib for the treatment of renal cell carcinoma
    Santoni, Matteo
    Massari, Francesco
    Piva, Francesco
    Carrozza, Francesco
    Di Nunno, Vincenzo
    Cimadamore, Alessia
    Martignetti, Angelo
    Montironi, Rodolfo
    Battelli, Nicola
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (09) : 1021 - 1025
  • [6] Chromophobe renal cell carcinoma-diagnosis and prognosis
    Erlmeier, F.
    PATHOLOGE, 2019, 40 (Suppl 3): : S252 - S258
  • [7] Renal Cell Carcinoma and Proteomics
    Sandim, Vanessa
    Pereira, Denise A.
    Ornellas, Antonio A.
    Alves, Gilda
    UROLOGIA INTERNATIONALIS, 2010, 84 (04) : 373 - 377
  • [8] Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
    Rodenburg, R. J.
    Eskens, F. A. L. M.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2019, 12 : 137 - 141
  • [9] Treatment selection in metastatic renal cell carcinoma: expert consensus
    Escudier, Bernard
    Szczylik, Cezary
    Porta, Camillo
    Gore, Martin
    NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (06) : 327 - 337
  • [10] Current Treatment Considerations in Metastatic Renal Cell Carcinoma
    Housam Haddad
    Brian I. Rini
    Current Treatment Options in Oncology, 2012, 13 : 212 - 229